Prothena Shares Fall After Trial Results Miss, Job Cuts

Dow Jones

May 27, 2025

By Katherine Hamilton

Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce.

The stock was down 27% to $4.81 in pre-market trading Tuesday.

The Irish biotechnology company said Friday its Phase 3 trial of a blood-disorder treatment had not met its primary or secondary endpoints. As a result, it was ending the trial, it said.

Oppenheimer analysts downgraded the Prothena stock to perform from outperform, and removed its price target. The analyst said they are still optimistic about the company's internal and partnered programs, but the trial was a main driver behind their thesis.

"We're moving to the sidelines for now," they said in a research note.

Chief Executive Daniel Welch called the results disappointing. He said Prothena is now planning what it called a substantial job cut in an effort to reduce expenses. It is also evaluating business options that it thinks could be in the best interest for shareholders.

The company expects to share more details about workforce reduction and business plans in June once they are more fleshed out.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 27, 2025 08:28 ET (12:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538466024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538466024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538466024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538466024","market":"us","top_or_hot":-1,"title":"Prothena Shares Fall After Trial Results Miss, Job Cuts","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce. \n</p>\n<p>\n  The stock was down 27% to $4.81 in pre-market trading Tuesday. \n</p>\n<p>\n  The Irish biotechnology company said Friday its Phase 3 trial of a blood-disorder treatment had not met its primary or secondary endpoints. As a result, it was ending the trial, it said. \n</p>\n<p>\n  Oppenheimer analysts downgraded the Prothena stock to perform from outperform, and removed its price target. The analyst said they are still optimistic about the company's internal and partnered programs, but the trial was a main driver behind their thesis. \n</p>\n<p>\n  \"We're moving to the sidelines for now,\" they said in a research note. \n</p>\n<p>\n  Chief Executive Daniel Welch called the results disappointing. He said Prothena is now planning what it called a substantial job cut in an effort to reduce expenses. It is also evaluating business options that it thinks could be in the best interest for shareholders. \n</p>\n<p>\n  The company expects to share more details about workforce reduction and business plans in June once they are more fleshed out. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena Shares Fall After Trial Results Miss, Job Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena Shares Fall After Trial Results Miss, Job Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-27 20:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce. \n</p>\n<p>\n  The stock was down 27% to $4.81 in pre-market trading Tuesday. \n</p>\n<p>\n  The Irish biotechnology company said Friday its Phase 3 trial of a blood-disorder treatment had not met its primary or secondary endpoints. As a result, it was ending the trial, it said. \n</p>\n<p>\n  Oppenheimer analysts downgraded the Prothena stock to perform from outperform, and removed its price target. The analyst said they are still optimistic about the company's internal and partnered programs, but the trial was a main driver behind their thesis. \n</p>\n<p>\n  \"We're moving to the sidelines for now,\" they said in a research note. \n</p>\n<p>\n  Chief Executive Daniel Welch called the results disappointing. He said Prothena is now planning what it called a substantial job cut in an effort to reduce expenses. It is also evaluating business options that it thinks could be in the best interest for shareholders. \n</p>\n<p>\n  The company expects to share more details about workforce reduction and business plans in June once they are more fleshed out. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538466024","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538466024","pubTimestamp":1748348880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce.The stock was down 27% to $4.81 in pre-market trading Tuesday.The Irish biotechnology company said Friday its Phase 3 trial of a blood-disorder treatment had not met its primary or secondary endpoints. As a result, it was ending the trial, it said.Oppenheimer analysts downgraded the Prothena stock to perform from outperform, and removed its price target. The analyst said they are still optimistic about the company's internal and partnered programs, but the trial was a main driver behind their thesis.\"We're moving to the sidelines for now,\" they said in a research note.Chief Executive Daniel Welch called the results disappointing. He said Prothena is now planning what it called a substantial job cut in an effort to reduce expenses. It is also evaluating business options that it thinks could be in the best interest for shareholders.The company expects to share more details abo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PRTA":"Prothena Corporation plc"},"translate_title":"Prothena股价因试验结果未达标、裁员而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Prothena shares fell after the company reported unfavorable trial results and said it would shrink its workforce. \n\n\n  The stock was down 27% to $4.81 in pre-market trading Tuesday. \n\n\n  The Irish biotechnology company said Friday its Phase 3 trial of a blood-disorder treatment had not met its primary or secondary endpoints. As a result, it was ending the trial, it said. \n\n\n  Oppenheimer analysts downgraded the Prothena stock to perform from outperform, and removed its price target. The analyst said they are still optimistic about the company's internal and partnered programs, but the trial was a main driver behind their thesis. \n\n\n  \"We're moving to the sidelines for now,\" they said in a research note. \n\n\n  Chief Executive Daniel Welch called the results disappointing. He said Prothena is now planning what it called a substantial job cut in an effort to reduce expenses. It is also evaluating business options that it thinks could be in the best interest for shareholders. \n\n\n  The company expects to share more details about workforce reduction and business plans in June once they are more fleshed out. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 08:28 ET (12:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}